TXG · CIK 0001770787
What 10x Genomics, Inc. told the SEC could break it.
10x Genomics' disclosures cluster on government policy and a thin reagent supply chain. Its biggest customer base is academic and government researchers whose buying tracks U.S. science funding, so funding freezes or the NIH's February 2025 move to cap indirect-cost rates at 15% could directly dampen demand for its tools. On the trade side, about 10% of its 2025 revenue comes from China, which it warns could be materially impacted or eliminated if Beijing retaliated against U.S. tariffs by adding 10x to its 'Unreliable Entity List'; and underneath, its recurring consumables business depends on single- or sole-source suppliers for critical enzymes and reagents — often without long-term contracts and with multi-month lead times — any disruption to which could halt product delivery.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- Dependence on U.S. academic/government research funding (NIH) — funding freezes/cuts and the Feb-2025 NIH 15% indirect-rate cap threaten customer demandmedium
10x's largest customer base is academic and government research institutions, whose purchasing depends on U.S. research funding — especially the National Institutes of Health (NIH). It warns that changes in U.S. academic/government regulations, policies or operations affecting research-funding terms could impair customers' ability to secure funding and, consequently, the timing and demand for its products — citing the February 2025 NIH move to impose a standard 15% indirect-cost rate, plus broader risks of freezes/reductions in NIH and other research funding. Because demand for single-cell/spatial genomics tools tracks research budgets, U.S. science-funding policy is a direct, material demand-side regulatory exposure.
“Any changes in U.S. academic and government regulations, policies or operations that affect the terms of research funding could impact our customers' ability to secure funding and, consequently, the timing and demand for our products and services.”
SEC filing →As of 2026 - China MOFCOM 'Unreliable Entity List' risk — China was ~10% of 2025 revenue and could be materially impacted or eliminated if 10x is added in retaliation for U.S. tariffsmedium
10x has direct exposure to U.S.–China decoupling. It notes China's Ministry of Commerce (MOFCOM) has previously added life-science companies to its 'Unreliable Entity List,' potentially in response to U.S. tariffs, and warns that if China expanded the list to include other life-sciences companies including 10x, its China business — approximately ten percent of total 2025 revenue — could be materially impacted or eliminated. With manufacturing also spanning Taiwan and Singapore and China/Taiwan sourcing exposure, escalating U.S.–China trade/retaliation policy is a specific, quantified geopolitical-regulatory threat to roughly a tenth of revenue.
Sole-source dependency
- Sole/single-source suppliers for critical enzymes, amplification mixes, reagents and oligonucleotides used in its consumables — no long-term contracts; multi-month lead timesmedium
10x Genomics and its customers depend on single- and sole-source suppliers for some of the equipment, components and materials used in its products. It specifically depends on a limited number of suppliers for the enzymes and amplification mixes used in its consumables, with some manufacturers being the sole source of certain necessary enzymes and reagents, and it does not have long-term contracts with many of these sole-source suppliers. Lead times for some of these components can run several months or more and have been extended by supply-chain disruptions. Because consumables (Chromium/Visium/Xenium kits) drive recurring revenue, a sole-source reagent disruption could halt product delivery. A genuine sole-source reagent/enzyme dependence.
“In some cases, these manufacturers are the sole source of certain necessary enzymes and reagents. We do not have long-term contracts with many of these sole source suppliers.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch